Biotech Stocks


Biotech Stocks

Biotechnology has been one of the fastest advancing industries in the past decade. With new medicine always being synthesized and new ways to fertilize crops, the sector is diverse and prosperous, especially as corporations look for new findings or better efficiency. Subsequently, the biotech stocks are booming and should continue to rise in the future.
Some of the best biotech stocks to buy in 2014 include Amgen (NYSE:AMGN) and Gilead Sciences (NYSE:GILD) although many smaller biotech corporations are on the rise and worth a consideration. Biotech stocks can cure your ailing portfolio and lead you down the road to recovery.

Biotechnology Sector Quote (CIX: MSECTOR5151)

3 Large-Cap Biotech Stocks to Hold for the Long Haul

Three large-cap biotech stocks to buy and hold for the long haul

7 Biotech Stocks to Buy for Q3

These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential.

6 Biotech Stocks to Buy Now Ahead of These June Catalysts

Biotech investors stand to make a windfall if they make calculated bets by thoroughly researching on key catalysts that could move the stocks in a big way.

7 Cheap Biotech Stocks to Buy Now

These biotech stocks are speculative, but could potentially blow up in the next couple of years with new treatments in the pipelines.

Cassava Sciences Just Returned to the Buy Zone

There's no need to panic about SAVA stock, as Cassava Sciences just launched an important study focused on treating Alzheimer's disease.

4 New Patents Add to Progenity’s Appeal

PROG stock has had its fair share of ups and downs. With a major executive-level change, however, Progenity looked poised for progress.

With Progress on Multiple Fronts, Bionano Genomics Stock Is Great Buy Here

Bionano's acquisition of a software company makes Saphyr more attractive, and studies should result in insurers reimbursing those who use the system. BNGO stock is a buy.

The 3 Biotech Firms Riding High on CRISPR News

Biotech stocks can be risky. If a clinical trial fails, you could very well lose your money. But choose wisely, and they can take off.

4 Stocks to Boost Your Portfolio (In an Unintuitive Way)

Moonshot investing can be risky, that's for sure. But if you learn from the mistakes of past moonshots, you can minimize your own.

7 A-Rated Biotech Stocks to Buy Now

Investors in search of long-term growth are increasingly choosing biotech stocks like BNTX stock and MRNA stock for their portfolios.

The Story of 2020 … and Possibly 2021 … and What it Means for Your Investments

In the not-too-distant future, healthcare will look dramatically different from what we know today. From telemedicine to precision medicine to genetic therapy, the global healthcare industry is about to be shaken up like never before.

With Pfizer Partnership, BioNTech Stock Should Push Higher

In light of a collaboration with a major drugmaker and a fast-track toward possible FDA approval, BNTX stock is practically irresistible.

Volatility May Continue, But CRISPR Stock Remains a Buy

Even after rebounding in recent weeks, consider now (or any pullback) prime time to enter a long-term position in CRISPR stock.

Repligen Stock: This Little-Known Biotech Posts Record Results

Repligen stock jumped 9% on the heels of the report to a new 52-week high of $203.90 today. And Louis Navellier sees a lot more upside for the company. Here's what potential RGEN stock investors should know.

Which Biotech Stocks Are a Buy on Earnings?

If you’re interested in high-growth biotech stocks with superior fundamentals, here are which ones to consider, and which ones to skip.

A New Healthcare Stock Pick in the Industry of the Decade

This company is riding a powerful trend in the future of healthcare. Plus, it offers high growth, a huge potential market and a path to profitability.

Biotech Boom: The Race for COVID-19 Vaccines

The pandemic highlights how far medical science has come. It also highlights how exciting the future is. While the Year of Biotech has been outstanding so far, we’re only seeing the beginning of a revolution.

Royalty Pharma’s Cash Flow Growth Will Power the Stock Higher

Royalty Pharma's cash flow growth will power the stock higher. If cash flow continues at this pace, RPRX stock could rise by at least 88% over the next three years.

Biotech Stocks: This Sector Outperformed the Market in Q2

Biotech stocks are breaking out of a seven-year consolidation phase -- and fast. But this rally isn’t slowing down anytime soon.